New data from the CAPTAIN trial shows that the TULSA Procedure, a whole-gland MRI-guided prostate ablation, preserves penile length significantly better than robotic radical prostatectomy (RP) one month after treatment. Patients undergoing TULSA had no median change in penile length, while those with robotic RP experienced a median reduction of 0.65 cm. This finding adds to previous CAPTAIN results showing TULSA's superiority in preserving erectile function and urinary continence at six months. The trial involved 211 men with intermediate-risk prostate cancer and aims to demonstrate TULSA's efficacy with better quality of life outcomes compared to robotic RP.
Crédit Agricole Normandie-Seine reported strong first-half 2026 results with record credit and deposit volumes, a 15.2 million euro increase in net banking income, and a 13.9% rise in net profit to 65.1 million euros. The bank's credit portfolio reac...
Virtual Investor Conferences announced that presentations from the July 22-23 Precious Metals & Critical Minerals Virtual Investor Conference are now available for on-demand viewing for 90 days. Investors can access company materials and schedule one...
EquipmentShare.com Inc. and some executives face a securities fraud lawsuit alleging they misled investors by not disclosing ongoing related-party transactions after their January 2026 IPO. The complaint claims founder-related entities continued undi...
BiomX's subsidiary Zorronet has partnered with Czech company Samura s.r.o. to expand its AI-powered monitoring technology across Central and Eastern Europe. The collaborations focus on smart pest management in agriculture and protecting critical tran...
Bloom Energy demonstrated strong Q1 2026 results with 130% year-over-year revenue growth, expanding profit margins, and positive guidance for the full year. The company is capitalizing on rising AI infrastructure needs by providing modular, on-site f...
